Navigation Links
Trial seeks improved lung-cancer screening by combining imaging and biomarkers
Date:5/3/2012

National Jewish Health is seeking to refine and improve lung-cancer screening by combining a blood test with CT imaging to detect disease earlier and more effectively. The trial combines a CT chest scan and the EarlyCDT-Lung blood test to screen for cancer, and seeks to build on recent research demonstrating that CT screening alone can reduce lung-cancer mortality.

"We have learned that CT screening of high-risk patients can reduce lung-cancer deaths. But we need to enhance screening to detect a greater number of early-stage lung cancers. That is the patient's best chance of a cure," said James Jett, MD, Professor of Medicine at National Jewish Health and principal investigator on the trial. "Combining CT screening with biomarker tests, such as the EarlyCDT-Lung, may help us detect more lung cancers at earlier stage while reducing the number of biopsies or operations performed for non-canceorus abnormalities."

EarlyCDT-Lung, developed by Oncimmune, Inc., detects antibodies that a person's immune system produces in its attempt to fight cancer. It has been shown that some antibodies may be detectable as long as five years before symptoms develop.

The National Lung Cancer Screening Trial recently demonstrated that screening patients with a high risk of developing cancer can reduce lung-cancer deaths by 20 percent. However, the CT screening also produces many false alarms, or false positives, which can lead to invasive follow-up testing, such as biopsy or surgery, that ends up finding only benign (non-cancerous) abnormalities. Researchers believe that the combination of the two tests, with their different detection strategies, may work together to make a screening method that is effective both medically and economically.

Lung cancer is the number one cause of cancer deaths in the United States, killing about 160,000 Americans every year; more than breast, colon and prostate cancer deaths combined. Early detection of lung cancer dramatically improves a patient's curative treatment options. Five-year survival for patients with advanced, stage IV disease is only 1 percent, while those whose cancer is detected early at stage I have a 70 to 80 percent of surviving five years. Five year-survival of all lung cancer in the United States is only 16 percent, because the disease is usually detected at an advanced stage when it becomes symptomatic.

"Early detection of cancer could dramatically improve survival and reduce the terrible toll it takes on people today," said Debra Dyer, MD, radiologist at National Jewish Health and co-principal investigator on the study. "We believe this study may demonstrate an effective method for doing just that."

The trial will screen 1,600 participants over 4 years. They will receive both the EarlyCDT-Lung blood test and a low-dose CT scan at no charge. Particpants need to be 50-75 years of age, have a smoking history of at least 20 pack-years (equivalent to a pack a day for 20 years), and be a current or former smoker who quit fewer than 10 years ago. Those who have a history of cancer other than skin cancer, serious illness that limits their life expectancy to less than 5 years, or currently use oxygen to breathe are not eligible for the study.


'/>"/>

Contact: William Allstetter
allstetterw@njhealth.org
303-398-1002
National Jewish Health
Source:Eurekalert

Related biology news :

1. Clinical trial launches to see whether vitamin D helps treat multiple sclerosis
2. New clinical trial explores novel noninvasive colon cancer screening test
3. Canadian Journal of Cardiology publishes new atrial fibrillation guidelines
4. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
5. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
6. Can industrial parks be more environmentally friendly?
7. Recruitment starts on MS hookworm trial
8. First vaccine against fatal visceral leishmaniasis enters clinical trial
9. Using online patient communities and new trial approaches to optimize clinical research
10. Sustainable land use strategies to support bioenergy described in Industrial Biotechnology journal
11. First industrial-scale foam forming research environment for forest sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... ... August 14, 2019 , ... Join Jonathan Riek, PhD, ... on Tuesday, September 10, 2019 at 1pm EDT to learn about two common ... management. , NAFLD is the most common diffuse liver disease, with a worldwide ...
(Date:8/14/2019)... ... August 14, 2019 , ... Gateway Genomics , a ... announces inclusion in the 38th annual Inc. 500|5000 list of fastest growing ... qualify, companies must have been founded and generating revenue by March 31, 2015. Ranking ...
(Date:8/14/2019)... (PRWEB) , ... August 13, 2019 , ... Dr. Julie Reck of Veterinary Medical ... to her patients. Her first stem cell patient, her own geriatric Australian Shepherd, Simon, ... to Dr. Reck, Simon wanted to play but his body was weak, and he struggled ...
Breaking Biology News(10 mins):
(Date:7/30/2019)... ... July 30, 2019 , ... The summer season has been ... Not only has the company already hosted many of its signature cooking classes ... its guests. , With Lajollacooks4u’s Private Cooking Parties, guests prepare and enjoy a ...
(Date:7/19/2019)... ... July 18, 2019 , ... ... Everest,” will be joining forces with California-based charity Coalition Duchenne for its 9th ... Coalition Duchenne raises awareness and funding for Duchenne muscular dystrophy and was founded ...
(Date:7/11/2019)... LAS VEGAS (PRWEB) , ... July 11, 2019 , ... ... 2019, R3 provided complimentary regenerative therapies to eight military Veterans under the R3 Heroes ... procedures being complimentary. , The R3 Heroes Program allow anyone to nominate a military ...
(Date:6/26/2019)... ... June 26, 2019 , ... Alice Branton today released ... improving physicochemical properties of Magnesium Gluconate, which can prove to be beneficial for treating ... of characteristic differentiation peak, change in crystallite size , Over 142% increase ...
Breaking Biology Technology: